ESR1 Mutations Affect Anti-proliferative Responses to Tamoxifen through Enhanced Cross-Talk with IGF Signaling

It is now generally accepted that estrogen receptor (ESR1) mutations occur frequently in metastatic breast cancers, however we do not yet know how to best treat these patients. We have modeled the three most frequent hormone binding ESR1 (HBD-ESR1) mutations (Y537N, Y537S, and D538G) using stable le...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Breast Cancer Res Treat
Autors principals: Gelsomino, Luca, Gu, Guowei, Rechoum, Yassine, Beyer, Amanda R, Pejerrey, Sasha M, Tsimelzon, Anna, Wang, Tao, Huffman, Kenneth, Ludlow, Andrew, Ando’, Sebastiano, Fuqua, Suzanne AW
Format: Artigo
Idioma:Inglês
Publicat: 2016
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5510243/
https://ncbi.nlm.nih.gov/pubmed/27178332
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-016-3829-5
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars